All In Biotech

Drug Trial Radar · NCT05281484

Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS

Three Intermediate Expanded Access Protocols for Amyotrophic Lateral Sclerosis With CNM-Au8. CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06

Last checked: Nov 19, 2026Latest source record: Aug 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Available

Status

Available

Enrollment

Not stated

Start

Not stated

Primary completion

Not stated

Sponsor

Lead sponsor
Clene NanomedicineIndustry
Sponsor type
Industry
First posted
Mar 16, 2022

More drug trials from this sponsor

Design

Study type
Expanded access
Who can join
All sexes, from 18 years

Summary

As written by the sponsor on the registry.

The primary objective of the intermediate expanded access protocol is to provide access to the investigational product, CNM-Au8, to up to 300 people living with ALS (pALS). No formal clinical hypotheses are being evaluated with concurrent controls. Secondary objectives include assessment of the safety of CNM-Au8 treatment in pALS. Safety will be assessed through the frequency of serious adverse events (SAEs), treatment-emergent adverse events (TEAEs) assessed as 'severe', discontinuations due to TEAEs, and laboratory abnormalities assessed as clinically significant during routine clinical monitoring (as applicable).

Conditions

  • Amyotrophic Lateral Sclerosis

Interventions

  • CNM-Au8Drug

    CNM-Au8 is an aqueous suspension of clean surfaced faceted nanocrystals consisting of gold atoms self-organized into crystals of various geometrical shapes (hexagonal bi-pyramid, pentagonal bipyramid, tetrahedron, decahedron, planar spheroids). Highly pure elemental Au nanocrystals are suspended in USP purified deionized water buffered with 0.546 mg/mL (6.5 mM) sodium bicarbonate (NaHCO3) nominally concentrated to up to 0.5 mg/mL (500 ppm).

Primary outcomes

What the sponsor says the trial is designed to measure.

No primary outcomes listed.

Locations

16 sites in 1 country. Site status is shown where the registry gives one.

  • Barrow Neurological Institute (Enrollment is full, not recruiting)

    Phoenix, Arizona · Available

  • UC Irvine (Enrollment is full, not recruiting)

    Orange, California · Available

  • Sutter Health (Enrollment is full, not recruiting)

    San Francisco, California · Available

  • Hospital for Special Care (Enrollment is full, not recruiting)

    New Britain, Connecticut · Available

  • Nova Southeastern University (Enrollment is full, not recruiting)

    Davie, Florida · Available

  • Northwestern (Enrollment is full, not recruiting)

    Chicago, Illinois · Available

  • University of Kansas (Enrollment is full, not recruiting)

    Fairway, Kansas · Available

  • Massachusetts General Hospital (Enrollment is full, not recruiting)

    Boston, Massachusetts · Available

  • Henry Ford Health Systems (Enrollment is full, not recruiting)

    Detroit, Michigan · Available

  • University of Nebraska Medical Center (Enrollment is full, not recruiting)

    Omaha, Nebraska · Available

  • DUKE University Medical Center

    Durham, North Carolina · Available

  • Providence Health (Enrollment is full, not recruiting)

    Portland, Oregon · Available

  • Penn State Health (Enrollment is full, not recruiting)

    Hershey, Pennsylvania · Available

  • Jefferson Hospital (Enrollment is full, not recruiting)

    Philadelphia, Pennsylvania · Available

  • Texas Neurology (Enrollment is full, not recruiting)

    Dallas, Texas · Available

  • University of Washington (Enrollment is full, not recruiting)

    Seattle, Washington · Available

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.